CBS-0550
 | |
| Systematic (IUPAC) name | |
|---|---|
|
N-[5-tert-butyl-2-(cyclopropylmethyl)-1-methylpyrazol-3-ylidene]-2-fluoro-3-(trifluoromethyl)benzamide | |
| Identifiers | |
| CAS Number | 887289-02-3 |
| PubChem | CID 24763642 |
| ChemSpider | 23320245 |
| Chemical data | |
| Formula | C20H23F4N3O |
| Molar mass | 397.409 g/mol |
| |
| |
CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects.[1] A number of related compounds have been developed with similar properties.[2]
See also
References
- ↑ Ohta H, et al. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. Bioorganic and Medicinal Chemistry. 2008 Feb 1;16(3):1111-24. PMID 18006322
- ↑ Hiroshi Ohta, Tomoko Ishizaka, Makoto Tatsuzuki, Mitsukane Yoshinaga, Izumi Iida, Yasumitsu Tomishima, Yoshihisa Toda, Shuji Saito (November 2007). "N-Alkylidenearylcarboxamides as new potent and selective CB2 cannabinoid receptor agonists with good oral bioavailability". Bioorganic & Medicinal Chemistry Letters 17 (22): 6299–6304. doi:10.1016/j.bmcl.2007.09.004. PMID 17884496.
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.